Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.
Identifieur interne : 001077 ( PubMed/Curation ); précédent : 001076; suivant : 001078Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.
Auteurs : Chai K. Lim [Australie] ; Ayse Bilgin [Australie] ; David B. Lovejoy [Australie] ; Vanessa Tan [Australie] ; Sonia Bustamante [Australie] ; Bruce V. Taylor [Australie] ; Alban Bessede [France] ; Bruce J. Brew [Australie] ; Gilles J. Guillemin [Australie]Source :
- Scientific reports [ 2045-2322 ] ; 2017.
Abstract
Activation of the kynurenine pathway (KP) of tryptophan metabolism results from chronic inflammation and is known to exacerbate progression of neurodegenerative disease. To gain insights into the links between inflammation, the KP and multiple sclerosis (MS) pathogenesis, we investigated the KP metabolomics profile of MS patients. Most significantly, we found aberrant levels of two key KP metabolites, kynurenic acid (KA) and quinolinic acid (QA). The balance between these metabolites is important as it determines overall excitotoxic activity at the N-methyl-D-Aspartate (NMDA) receptor. We also identified that serum KP metabolic signatures in patients can discriminate clinical MS subtypes with high sensitivity and specificity. A C5.0 Decision Tree classification model discriminated the clinical subtypes of MS with a sensitivity of 91%. After validation in another independent cohort, sensitivity was maintained at 85%. Collectively, our studies suggest that abnormalities in the KP may be associated with the switch from early-mild stage MS to debilitating progressive forms of MS and that analysis of KP metabolites in MS patient serum may have application as MS disease biomarkers.
DOI: 10.1038/srep41473
PubMed: 28155867
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001080
Links to Exploration step
pubmed:28155867Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.</title><author><name sortKey="Lim, Chai K" sort="Lim, Chai K" uniqKey="Lim C" first="Chai K" last="Lim">Chai K. Lim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Bilgin, Ayse" sort="Bilgin, Ayse" uniqKey="Bilgin A" first="Ayse" last="Bilgin">Ayse Bilgin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Statistics, Faculty of Science and Engineering, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Statistics, Faculty of Science and Engineering, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Lovejoy, David B" sort="Lovejoy, David B" uniqKey="Lovejoy D" first="David B" last="Lovejoy">David B. Lovejoy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Tan, Vanessa" sort="Tan, Vanessa" uniqKey="Tan V" first="Vanessa" last="Tan">Vanessa Tan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Bustamante, Sonia" sort="Bustamante, Sonia" uniqKey="Bustamante S" first="Sonia" last="Bustamante">Sonia Bustamante</name><affiliation wicri:level="1"><nlm:affiliation>Bioanalytical Mass Spectrometry Facility, University of New South Wales, NSW 2052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Bioanalytical Mass Spectrometry Facility, University of New South Wales, NSW 2052</wicri:regionArea></affiliation></author><author><name sortKey="Taylor, Bruce V" sort="Taylor, Bruce V" uniqKey="Taylor B" first="Bruce V" last="Taylor">Bruce V. Taylor</name><affiliation wicri:level="1"><nlm:affiliation>Menzies Research Institute Tasmania, University of Tasmania, TAS 7000, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Menzies Research Institute Tasmania, University of Tasmania, TAS 7000</wicri:regionArea></affiliation></author><author><name sortKey="Bessede, Alban" sort="Bessede, Alban" uniqKey="Bessede A" first="Alban" last="Bessede">Alban Bessede</name><affiliation wicri:level="1"><nlm:affiliation>ImmuSmol, Pessac, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ImmuSmol, Pessac</wicri:regionArea></affiliation></author><author><name sortKey="Brew, Bruce J" sort="Brew, Bruce J" uniqKey="Brew B" first="Bruce J" last="Brew">Bruce J. Brew</name><affiliation wicri:level="1"><nlm:affiliation>Peter Duncan Neurosciences Research Unit, St Vincent's Centre for Applied Medical Research, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter Duncan Neurosciences Research Unit, St Vincent's Centre for Applied Medical Research, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Guillemin, Gilles J" sort="Guillemin, Gilles J" uniqKey="Guillemin G" first="Gilles J" last="Guillemin">Gilles J. Guillemin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28155867</idno><idno type="pmid">28155867</idno><idno type="doi">10.1038/srep41473</idno><idno type="wicri:Area/PubMed/Corpus">001080</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001080</idno><idno type="wicri:Area/PubMed/Curation">001077</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001077</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.</title><author><name sortKey="Lim, Chai K" sort="Lim, Chai K" uniqKey="Lim C" first="Chai K" last="Lim">Chai K. Lim</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Bilgin, Ayse" sort="Bilgin, Ayse" uniqKey="Bilgin A" first="Ayse" last="Bilgin">Ayse Bilgin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Statistics, Faculty of Science and Engineering, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Statistics, Faculty of Science and Engineering, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Lovejoy, David B" sort="Lovejoy, David B" uniqKey="Lovejoy D" first="David B" last="Lovejoy">David B. Lovejoy</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Tan, Vanessa" sort="Tan, Vanessa" uniqKey="Tan V" first="Vanessa" last="Tan">Vanessa Tan</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author><author><name sortKey="Bustamante, Sonia" sort="Bustamante, Sonia" uniqKey="Bustamante S" first="Sonia" last="Bustamante">Sonia Bustamante</name><affiliation wicri:level="1"><nlm:affiliation>Bioanalytical Mass Spectrometry Facility, University of New South Wales, NSW 2052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Bioanalytical Mass Spectrometry Facility, University of New South Wales, NSW 2052</wicri:regionArea></affiliation></author><author><name sortKey="Taylor, Bruce V" sort="Taylor, Bruce V" uniqKey="Taylor B" first="Bruce V" last="Taylor">Bruce V. Taylor</name><affiliation wicri:level="1"><nlm:affiliation>Menzies Research Institute Tasmania, University of Tasmania, TAS 7000, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Menzies Research Institute Tasmania, University of Tasmania, TAS 7000</wicri:regionArea></affiliation></author><author><name sortKey="Bessede, Alban" sort="Bessede, Alban" uniqKey="Bessede A" first="Alban" last="Bessede">Alban Bessede</name><affiliation wicri:level="1"><nlm:affiliation>ImmuSmol, Pessac, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>ImmuSmol, Pessac</wicri:regionArea></affiliation></author><author><name sortKey="Brew, Bruce J" sort="Brew, Bruce J" uniqKey="Brew B" first="Bruce J" last="Brew">Bruce J. Brew</name><affiliation wicri:level="1"><nlm:affiliation>Peter Duncan Neurosciences Research Unit, St Vincent's Centre for Applied Medical Research, Sydney, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Peter Duncan Neurosciences Research Unit, St Vincent's Centre for Applied Medical Research, Sydney</wicri:regionArea></affiliation></author><author><name sortKey="Guillemin, Gilles J" sort="Guillemin, Gilles J" uniqKey="Guillemin G" first="Gilles J" last="Guillemin">Gilles J. Guillemin</name><affiliation wicri:level="1"><nlm:affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109</wicri:regionArea></affiliation></author></analytic><series><title level="j">Scientific reports</title><idno type="eISSN">2045-2322</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Activation of the kynurenine pathway (KP) of tryptophan metabolism results from chronic inflammation and is known to exacerbate progression of neurodegenerative disease. To gain insights into the links between inflammation, the KP and multiple sclerosis (MS) pathogenesis, we investigated the KP metabolomics profile of MS patients. Most significantly, we found aberrant levels of two key KP metabolites, kynurenic acid (KA) and quinolinic acid (QA). The balance between these metabolites is important as it determines overall excitotoxic activity at the N-methyl-D-Aspartate (NMDA) receptor. We also identified that serum KP metabolic signatures in patients can discriminate clinical MS subtypes with high sensitivity and specificity. A C5.0 Decision Tree classification model discriminated the clinical subtypes of MS with a sensitivity of 91%. After validation in another independent cohort, sensitivity was maintained at 85%. Collectively, our studies suggest that abnormalities in the KP may be associated with the switch from early-mild stage MS to debilitating progressive forms of MS and that analysis of KP metabolites in MS patient serum may have application as MS disease biomarkers.</div></front></TEI><pubmed><MedlineCitation Status="In-Data-Review" Owner="NLM"><PMID Version="1">28155867</PMID><DateCreated><Year>2017</Year><Month>02</Month><Day>03</Day></DateCreated><DateRevised><Year>2017</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>7</Volume><PubDate><Year>2017</Year><Month>Feb</Month><Day>03</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.</ArticleTitle><Pagination><MedlinePgn>41473</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1038/srep41473</ELocationID><Abstract><AbstractText>Activation of the kynurenine pathway (KP) of tryptophan metabolism results from chronic inflammation and is known to exacerbate progression of neurodegenerative disease. To gain insights into the links between inflammation, the KP and multiple sclerosis (MS) pathogenesis, we investigated the KP metabolomics profile of MS patients. Most significantly, we found aberrant levels of two key KP metabolites, kynurenic acid (KA) and quinolinic acid (QA). The balance between these metabolites is important as it determines overall excitotoxic activity at the N-methyl-D-Aspartate (NMDA) receptor. We also identified that serum KP metabolic signatures in patients can discriminate clinical MS subtypes with high sensitivity and specificity. A C5.0 Decision Tree classification model discriminated the clinical subtypes of MS with a sensitivity of 91%. After validation in another independent cohort, sensitivity was maintained at 85%. Collectively, our studies suggest that abnormalities in the KP may be associated with the switch from early-mild stage MS to debilitating progressive forms of MS and that analysis of KP metabolites in MS patient serum may have application as MS disease biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lim</LastName><ForeName>Chai K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology, School of Medical Sciences, University of New South Wales, NSW 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bilgin</LastName><ForeName>Ayse</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Statistics, Faculty of Science and Engineering, Macquarie University, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lovejoy</LastName><ForeName>David B</ForeName><Initials>DB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bustamante</LastName><ForeName>Sonia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bioanalytical Mass Spectrometry Facility, University of New South Wales, NSW 2052, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bruce V</ForeName><Initials>BV</Initials><AffiliationInfo><Affiliation>Menzies Research Institute Tasmania, University of Tasmania, TAS 7000, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bessede</LastName><ForeName>Alban</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>ImmuSmol, Pessac, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brew</LastName><ForeName>Bruce J</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Peter Duncan Neurosciences Research Unit, St Vincent's Centre for Applied Medical Research, Sydney, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, St Vincent's Hospital, Sydney, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guillemin</LastName><ForeName>Gilles J</ForeName><Initials>GJ</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Faculty of Medicine and Health Sciences, Macquarie University, NSW 2109, Australia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Peter Duncan Neurosciences Research Unit, St Vincent's Centre for Applied Medical Research, Sydney, Australia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>J Interferon Cytokine Res. 2001 Dec;21(12):1097-101</RefSource><PMID Version="1">11798468</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Neurol. 2009 Mar;65(3):239-48</RefSource><PMID Version="1">19334069</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroinflammation. 2014 Dec 13;11:204</RefSource><PMID Version="1">25498310</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Immunol. 2004 Oct;4(10):762-74</RefSource><PMID Version="1">15459668</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Anal Biochem. 2002 Feb 1;301(1):21-6</RefSource><PMID Version="1">11811963</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FASEB J. 2005 Aug;19(10):1347-9</RefSource><PMID Version="1">15939737</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2014 Jul 10;511(7508):184-90</RefSource><PMID Version="1">24930766</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tryptophan Res. 2009;2:1-19</RefSource><PMID Version="1">22084578</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 2005 Dec 22;438(7071):1167-71</RefSource><PMID Version="1">16372012</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 2001;102(3):687-95</RefSource><PMID Version="1">11226705</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Proc Natl Acad Sci U S A. 2010 Nov 30;107(48):20768-73</RefSource><PMID Version="1">21068375</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Neurosci. 1999 Nov;11(11):3857-63</RefSource><PMID Version="1">10583474</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Behav Immun. 2016 Jan;51:47-55</RefSource><PMID Version="1">26189678</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neuroinflammation. 2011 Aug 10;8:94</RefSource><PMID Version="1">21831269</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Med. 2000 Jan;6(1):67-70</RefSource><PMID Version="1">10613826</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tryptophan Res. 2009;2:71-9</RefSource><PMID Version="1">22084583</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Tryptophan Res. 2010;3:157-67</RefSource><PMID Version="1">22084596</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurosci. 2009 Apr 1;29(13):4200-9</RefSource><PMID Version="1">19339614</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Mol Psychiatry. 2010 Apr;15(4):393-403</RefSource><PMID Version="1">19918244</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>FEBS J. 2012 Apr;279(8):1356-65</RefSource><PMID Version="1">22248144</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacol Rev. 1993 Sep;45(3):309-79</RefSource><PMID Version="1">8248282</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neuroscience. 1997 Jun;78(4):967-75</RefSource><PMID Version="1">9174065</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Jun 25;10(6):e0130715</RefSource><PMID Version="1">26110930</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain Res. 2013 Nov 6;1537:267-72</RefSource><PMID Version="1">23973746</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Rapid Commun Mass Spectrom. 2009 May;23(9):1371-9</RefSource><PMID Version="1">19337982</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurol. 2015 Oct;11(10):585-96</RefSource><PMID Version="1">26392381</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Neurochem. 2001 Aug;78(4):842-53</RefSource><PMID Version="1">11520905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>PLoS One. 2015 Jun 26;10(6):e0131389</RefSource><PMID Version="1">26114426</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurol Neuroimmunol Neuroinflamm. 2015 Dec 24;3(1):e185</RefSource><PMID Version="1">26740964</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cell. 2015 Sep 10;162(6):1338-52</RefSource><PMID Version="1">26359987</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Brain. 2009 May;132(Pt 5):1146-60</RefSource><PMID Version="1">19321461</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Arch Neurol. 2001 Jul;58(7):1081-6</RefSource><PMID Version="1">11448297</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Annu Rev Neurosci. 2008;31:247-69</RefSource><PMID Version="1">18558855</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Autism Res. 2016 Jun;9(6):621-31</RefSource><PMID Version="1">26497015</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Glia. 2005 Jan 1;49(1):15-23</RefSource><PMID Version="1">15390107</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Proteomics. 2012 Aug 3;75(15):4802-19</RefSource><PMID Version="1">22634087</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Neurosci Lett. 1984 Aug 10;48(3):273-8</RefSource><PMID Version="1">6237279</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Several authors (C.K.L., G.J.G. and B.J.B.) are named inventors on international patent specifications “Method and prognostic kit for monitoring multiple sclerosis (MS)” initially published in 2013 (WO/2015/008111) that contain partial information found in this manuscript. All other authors declare no competing financial interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>2</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>2</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28155867</ArticleId><ArticleId IdType="pii">srep41473</ArticleId><ArticleId IdType="doi">10.1038/srep41473</ArticleId><ArticleId IdType="pmc">PMC5290739</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001077 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001077 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:28155867
|texte= Kynurenine pathway metabolomics predicts and provides mechanistic insight into multiple sclerosis progression.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:28155867" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |